X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs WOCKHARDT LTD. - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA WOCKHARDT LTD. GLENMARK PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 25.3 -22.0 - View Chart
P/BV x 4.0 2.2 177.4% View Chart
Dividend Yield % 0.3 0.0 17,641.8%  

Financials

 GLENMARK PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
WOCKHARDT LTD.
Mar-18
GLENMARK PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs9931,012 98.1%   
Low Rs729532 137.2%   
Sales per share (Unadj.) Rs325.5355.9 91.5%  
Earnings per share (Unadj.) Rs39.3-60.3 -65.2%  
Cash flow per share (Unadj.) Rs48.7-46.8 -104.1%  
Dividends per share (Unadj.) Rs2.000.01 20,000.0%  
Dividend yield (eoy) %0.20 17,923.7%  
Book value per share (Unadj.) Rs159.2257.8 61.8%  
Shares outstanding (eoy) m282.17110.63 255.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.62.2 122.0%   
Avg P/E ratio x21.9-12.8 -171.2%  
P/CF ratio (eoy) x17.7-16.5 -107.2%  
Price / Book Value ratio x5.43.0 180.7%  
Dividend payout %5.10 -30,680.5%   
Avg Mkt Cap Rs m242,99185,379 284.6%   
No. of employees `00013.06.3 207.3%   
Total wages/salary Rs m16,4089,371 175.1%   
Avg. sales/employee Rs Th7,083.96,295.0 112.5%   
Avg. wages/employee Rs Th1,265.41,498.3 84.5%   
Avg. net profit/employee Rs Th855.1-1,066.3 -80.2%   
INCOME DATA
Net Sales Rs m91,85739,369 233.3%  
Other income Rs m3741,202 31.1%   
Total revenues Rs m92,23040,571 227.3%   
Gross profit Rs m20,36718 111,295.4%  
Depreciation Rs m2,6441,495 176.8%   
Interest Rs m2,3732,555 92.9%   
Profit before tax Rs m15,724-2,830 -555.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-810-3,582 22.6%   
Tax Rs m3,827257 1,489.0%   
Profit after tax Rs m11,088-6,669 -166.3%  
Gross profit margin %22.20 47,700.2%  
Effective tax rate %24.3-9.1 -268.0%   
Net profit margin %12.1-16.9 -71.3%  
BALANCE SHEET DATA
Current assets Rs m68,74633,796 203.4%   
Current liabilities Rs m27,02726,917 100.4%   
Net working cap to sales %45.417.5 259.9%  
Current ratio x2.51.3 202.6%  
Inventory Days Days8579 107.1%  
Debtors Days Days9689 107.1%  
Net fixed assets Rs m24,13239,664 60.8%   
Share capital Rs m282553 51.0%   
"Free" reserves Rs m44,64327,968 159.6%   
Net worth Rs m44,92528,522 157.5%   
Long term debt Rs m45,36321,731 208.7%   
Total assets Rs m117,63981,620 144.1%  
Interest coverage x7.6-0.1 -7,092.3%   
Debt to equity ratio x1.00.8 132.5%  
Sales to assets ratio x0.80.5 161.9%   
Return on assets %11.4-5.0 -227.0%  
Return on equity %24.7-23.4 -105.6%  
Return on capital %19.1-7.7 -249.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,1529,807 572.6%   
Fx outflow Rs m8,0841,789 452.0%   
Net fx Rs m48,0688,019 599.5%   
CASH FLOW
From Operations Rs m6,574684 960.6%  
From Investments Rs m-7,1246,302 -113.0%  
From Financial Activity Rs m5,432-7,695 -70.6%  
Net Cashflow Rs m1,992-664 -300.1%  

Share Holding

Indian Promoters % 48.3 74.5 64.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 2.3 300.0%  
FIIs % 34.4 7.7 446.8%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.5 15.4 68.2%  
Shareholders   56,727 67,757 83.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   WYETH LTD  IPCA LABS  JUBILANT LIFE SCIENCES  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Stock Market's Sudden Crash; Rising Oil Prices; Banking Stocks and Top Cues in Action Today(Pre-Open)

The Indian share markets ended lower on Friday. The S&P BSE Sensex partially recovered after crashing 1,000 points in intraday trade to settle 280 points lower.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS